Bristlecone Advisors Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Bristlecone Advisors reduced its stake in Amgen by 5.32% during the most recent quarter end. The investment management company now holds a total of 16,627 shares of Amgen which is valued at $2,732,149 after selling 935 shares in Amgen , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Amgen makes up approximately 1.00% of Bristlecone Advisors’s portfolio.

Other Hedge Funds, Including , Carl Domino Inc reduced its stake in AMGN by selling 12 shares or 0.13% in the most recent quarter. The Hedge Fund company now holds 8,900 shares of AMGN which is valued at $1,462,448. Amgen makes up approx 1.39% of Carl Domino Inc’s portfolio.Gradient Investments boosted its stake in AMGN in the latest quarter, The investment management firm added 537 additional shares and now holds a total of 30,739 shares of Amgen which is valued at $5,173,681. Amgen makes up approx 0.51% of Gradient Investments’s portfolio.Reilly Herbert Faulkner Iii boosted its stake in AMGN in the latest quarter, The investment management firm added 580 additional shares and now holds a total of 26,933 shares of Amgen which is valued at $4,533,093. Amgen makes up approx 3.41% of Reilly Herbert Faulkner Iii’s portfolio.North Star Asset Management Inc reduced its stake in AMGN by selling 100 shares or 5.32% in the most recent quarter. The Hedge Fund company now holds 1,781 shares of AMGN which is valued at $297,854. Amgen makes up approx 0.03% of North Star Asset Management Inc’s portfolio.

Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.